论文部分内容阅读
目的:评价在CT导引下瘤体内125Ⅰ粒子永久性植入治疗恶性肿瘤的安全性及其疗效。方法:8例12个病灶(10次)行CT导引下瘤体内125Ⅰ粒子植入,在CT导引下穿刺植入125Ⅰ粒子。植入术后立即及术后2～5个月行CT扫描观察粒子在瘤体内的分布、有无并发症发生及疗效。结果:8例粒子植入均顺利完成,粒子分布满意,单个瘤体内植入125Ⅰ粒子数为2～60粒(平均32.5粒)。未见急性并发症和与治疗相关的放射损伤。CT检查示3个病灶消失,7个病灶明显缩小,其余2个病灶大小无明显变化。植入术前及植入术后病灶平均直径分别为4.02cm和2.16cm(t=3.62,P<0.05)。结论:CT导引下125Ⅰ粒子植入近距离放射治疗对原发及转移性恶性肿瘤的近期治疗效果满意。
OBJECTIVE: To evaluate the safety and efficacy of permanent implantation of 125I particles in malignant tumors under CT guidance. Methods: Eighty patients with 12 lesions (10 times) underwent CT-guided implantation of 125I particles in the tumor. 125I seeds were implanted under CT guidance. Immediately after implantation and 2 to 5 months after operation, the CT scan was used to observe the distribution of the particles in the tumor, with or without complications and curative effects. Results: All the 8 cases were successfully completed and the distribution of the particles was satisfactory. The number of 125I seeds implanted in a single tumor ranged from 2 to 60 (an average of 32.5). No acute complications or radiation-related injuries were observed. CT examination showed three lesions disappeared, seven lesions were significantly reduced, the remaining two lesions no significant change in size. The average diameters of the lesions before and after implantation were 4.02 cm and 2.16 cm, respectively (t = 3.62, P <0.05). CONCLUSION: CT guided 125I brachytherapy with brachytherapy is effective in the treatment of primary and metastatic malignancies.